Moolec Science (MLECW) Total Current Liabilities (2022 - 2025)
Moolec Science (MLECW) posted Total Current Liabilities of $61.9 million for Q4 2025, down 73.78% sequentially from $236.1 million in Q2 2025, and up 858.22% YoY from $6.5 million in Q4 2024.
Moolec Science (MLECW) Total Current Liabilities (2022 - 2025) Analysis & Trends
Moolec Science has reported Total Current Liabilities for 4 years, with the latest figure at $61.9 million in Q4 2025.
- Quarterly Total Current Liabilities rose 858.22% year-over-year to $61.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $61.9 million (up 858.22% YoY) and the FY2025 annual result came in at $236.1 million, down 44.77% from the prior year.
- Total Current Liabilities fell to $61.9 million in Q4 2025 per MLECW's latest filing, from $236.1 million in the prior quarter.
- Over five years, Total Current Liabilities peaked at $427.4 million in Q2 2024 and troughed at $2.9 million in Q1 2023.
- A 4-year average of $68.0 million and a median of $9.8 million in 2022 frame the typical range for Total Current Liabilities.
- The sharpest annual moves came in 2024 and 2025: Total Current Liabilities soared 1312.97% in 2024, then plunged 44.77% in 2025.
- Over 4 years, Total Current Liabilities stood at $11.3 million in 2022, then declined by 26.57% to $8.3 million in 2023, then declined by 22.02% to $6.5 million in 2024, then jumped by 858.22% to $61.9 million in 2025.
- According to Business Quant data, Total Current Liabilities over the past three periods registered $61.9 million, $236.1 million, and $6.5 million for Q4 2025, Q2 2025, and Q4 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.51 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 2.49 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 438.74 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 630.93 Mn |
| 10 | Moolec Science | 8,617.72 | -1.19 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 61.88 Mn |
| Jun 30, 2025 | 236.05 Mn |
| Dec 31, 2024 | 6.46 Mn |
| Sep 30, 2024 | 7.36 Mn |
| Jun 30, 2024 | 427.40 Mn |
| Mar 31, 2024 | 7.82 Mn |
| Dec 31, 2023 | 8.28 Mn |
| Sep 30, 2023 | 12.51 Mn |
| Jun 30, 2023 | 30.25 Mn |
| Mar 31, 2023 | 2.92 Mn |
| Dec 31, 2022 | 11.28 Mn |
| Jun 30, 2022 | 4.09 Mn |